TY  - JOUR
AU  - Starace, M
AU  - Iorizzo, M
AU  - Sechi, A
AU  - Alessandrini, AM
AU  - Carpanese, M
AU  - Bruni, F
AU  - Vara, G
AU  - Apalla, Z
AU  - Asz-Sigall, D
AU  - Barruscotti, S
AU  - Camacho, F
AU  - Doche, I
AU  - Estrada, BD
AU  - Dhurat, R
AU  - Gavazzoni, MF
AU  - Grimalt, R
AU  - Harries, M
AU  - Ioannidis, D
AU  - McMichael, A
AU  - Melo, DF
AU  - Oliveira, R
AU  - Ovcharenko, Y
AU  - Pirmez, R
AU  - Ramot, Y
AU  - Rudnicka, L
AU  - Shapiro, J
AU  - Silyuk, T
AU  - Sinclair, R
AU  - Tosti, A
AU  - Vano-Galvan, S
AU  - Piraccini, BM
Y2  - 2021/10/13
Y1  - 2021/12
SN  - 2666-3287
UR  - http://hdl.handle.net/11343/288093
AB  - Background: The cutaneous manifestations of COVID-19 may be useful disease markers and prognostic indicators. Recently, postinfectious telogen effluvium and trichodynia have also been reported. Objective: To evaluate the presence of trichodynia and telogen effluvium in patients with COVID-19 and describe their characteristics in relation to the other signs and symptoms of the disease. Methods: Patients with a history of COVID-19 presenting to the clinics of a group of hair experts because of telogen effluvium and/or scalp symptoms were questioned about their hair signs and symptoms in relation to the severity of COVID-19 and associated symptoms. Results: Data from 128 patients were collected. Telogen effluvium was observed in 66.3% of the patients and trichodynia in 58.4%. Trichodynia was associated with telogen effluvium in 42.4% of the cases and anosmia and ageusia in 66.1% and 44.1% of the cases, respectively. In majority (62.5%) of the patients, the hair signs and symptoms started within the first month after COVID-19 diagnosis, and in 47.8% of the patients, these started after 12 weeks or more. Limitations: The recruitment of patients in specialized hair clinics, lack of a control group, and lack of recording of patient comorbidities. Conclusion: The severity of postviral telogen effluvium observed in patients with a history of COVID-19 infection may be influenced by COVID-19 severity. We identified early-onset (<4 weeks) and late-onset (>12 weeks) telogen effluvium.
LA  - eng
PB  - Elsevier BV
T1  - Trichodynia and telogen effluvium in COVID-19 patients: Results of an international expert opinion survey on diagnosis and management.
DO  - 10.1016/j.jdin.2021.07.006
IS  - JAAD Int
VL  - 5
SP  - 11-18
ER  -